氧化应激可造成心血管组织损伤，是引发心血管疾病的原因之一。拮抗氧化应激对心血管疾病的治疗具有重要意义。贵州中药注射剂大品种参芎葡萄糖注射液（SGI）是临床常用的心血管疾病治疗药物，年销售额达12亿元。本课题组前期研究发现，SGI可激活PI3K/Akt通路产生较强的抗氧化应激作用。但迄今为止，SGI抗氧化应激的药效物质基础尚未明确，限制了该产品有效性和安全性的进一步提升。本课题拟使用磷酸化蛋白组学、小分子-蛋白相互作用组学、生物信息学和文献分析等手段，筛选SGI调控PI3K/Akt通路所作用的上游靶蛋白，并用细胞模型进行靶蛋白确证。体外表达已确证的靶蛋白，利用亲和超滤结合液相色谱-质谱技术，筛选鉴定SGI中与靶蛋白结合的小分子，最后用细胞和动物模型进行小分子活性验证和组方优化，由此阐明SGI抗氧化应激的药效物质基础，为进一步提升SGI的药效和安全性提供创新思路和实验依据。

Oxidative stress may directly cause cardiovascular system injury, which is an important factor leading to cardiovascular diseases. Therefore, it is of great importance to prevent oxidative stress for the treatment of cardiovascular disease. Shengxiong glucose injection (SGI), a traditional Chinese medicine injection produced by Guizhou with sales of 1.2 billion per year, is clinically effective and widely used for the treatment of various cardiovascular diseases. Our previous investigations showed that SGI could exert a strong anti-oxidative stress effect by activating PI3K/Akt pathway. Up to now, the active components of anti-oxidative activity of SGI are still unclear, which retards the deep exploitation of SGI. In the current project, the mechanism of the regulation of PI3K/Akt pathway by the SGI will be further investigated to identify the target proteins, which are heterologously expressed afterwards. Then, by using affinity ultrafiltration coupled with liquid chromatography-mass spectrometry (LC-MS) technology, the chemicals bound to the heterologously expressed proteins will be isolated and identified. In addition, these chemicals will be evaluated and the formula of these chemicals will be optimized by using cell and animal models. Our results may provide a new approach for the improvement of efficacy and safety of SGI.